, /


1/9

BY

APPROVED

CSESSE: CZECC

ANTI-WT126-34 CTL



E: T RATIO

*Fig.* 1

V

P


2/9 0 APPROVED ORAFTSMAN 6 **TARGET CELLS** ANTI-HU WT126-34 CTL T2 다 ocaste . Esezec 50-O T2+P12  $\diamond$ % SPECIFIC LYSIS 40-**BV173** 30-**LEUK-697** 20-**MV441** n  $\mathcal{S}$ 10-CD34+CELLS **⊕** □ **CML PATIENT** 田 0 2.5:1-10 -1:01 T <u>...</u>

E: T RATIO

*Fig. 2* 



ogezge.czecc



3/9

E: T RATIO


*Fig. 3* 

0.5:1

HIQ. 4.

LINE 85 LINE 65 LINE 81 LINE 62 LINE 77 LINE **CTL LINES** DRAFTSMAN ß ģ 10-2 P126 PEPTIDE CONC. (nM) 10<sup>4</sup> 10<sup>3</sup> 10<sup>2</sup> 10<sup>1</sup> 10<sup>0</sup> 10<sup>-1</sup> Ð Ħ О  $\triangleleft$ 60-80 -101 20-0 **% SPECIFIC KILLING** 

4/9



**SUBSTITUTE SHEET (RULE 26)** 

D9625962 . O72600


**SCLASS** 

0

APPROVED

 $\swarrow$ 


WO.00/26249



E: T RATIO


*Fig.* 4*C* 

6/9 APPROVED (0.G. FIG. K562-A2 Fig. Α C1R-A2 **BV173** K562 697 DRAFTSMAN VT-1 ABL CML CML NORMAL Β CD34+ CD34+ CD34+ CD34+ CD34-CD34+ CD34+ CD34-**BV173** CD34-CD34+ **CD34-VT-1** 1.13 ABL NORMAL CML С CD34+ C1R-A2 CD34-CD34+ CD34+ CD34+ CD34-BV173 K562 697 VT-1 -ACTIN -




## PCT/GB99/03572





E: T RATIO





**SUBSTITUTE SHEET (RULE 26)** 

SUBCLASS

CLASSISUB

APPROVED

à

DRAFTSMAN

